

# Human IL 12/23 (Briakinumab) Antibody

## Biotin

Biosimilar Recombinant Human Monoclonal Antibody

### Product Information

**Product No.:** LT501

**Clone:** ABT-874

**Isotype:** AB\_2893963

**RRID:** Human IgG1 $\lambda$

**Storage:** Sterile 2° to 8°C

### Product Description

#### Specificity:

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.

#### Antigen Distribution:

IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.

#### Background:

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23 $\alpha$  to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

#### Known Reactivity Species:

Human

#### Expression Host:

HEK-293 Cells

#### Format:

Biotin

#### Immunogen:

This antibody was produced by phage display technology.

#### Formulation

This biotin conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

#### Storage and Stability

This biotinylated monoclonal antibody is stable when stored at 2° to 8°C.

#### Do not freeze

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminster Dr, St. Louis, MO 63026

(800) 538-1145

leincoglobal@leinco.com

## Applications

### Applications and Recommended Usage (Quality Tested By Leinco):

**FC** The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is  $\leq 1.0 \mu\text{g}$  per  $10^6$  cells in a volume of 100  $\mu\text{l}$ . Titration of the reagent is recommended for optimal performance for each application.

### ELISA

### Other Applications Reported in Literature:

FA

### Country of Origin

USA

### References

- 1) Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123